JP2010532787A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010532787A5 JP2010532787A5 JP2010516038A JP2010516038A JP2010532787A5 JP 2010532787 A5 JP2010532787 A5 JP 2010532787A5 JP 2010516038 A JP2010516038 A JP 2010516038A JP 2010516038 A JP2010516038 A JP 2010516038A JP 2010532787 A5 JP2010532787 A5 JP 2010532787A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- mucositis
- patient
- item
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028116 Mucosal inflammation Diseases 0.000 claims description 26
- 201000010927 Mucositis Diseases 0.000 claims description 26
- 239000000556 agonist Substances 0.000 claims description 26
- 238000002512 chemotherapy Methods 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 238000001959 radiotherapy Methods 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 208000000718 duodenal ulcer Diseases 0.000 claims description 3
- 201000005917 gastric ulcer Diseases 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 150000003384 small molecules Chemical group 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010063655 Erosive oesophagitis Diseases 0.000 claims description 2
- 206010017865 Gastritis erosive Diseases 0.000 claims description 2
- 206010064147 Gastrointestinal inflammation Diseases 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010030216 Oesophagitis Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 231100000026 common toxicity Toxicity 0.000 claims description 2
- 230000001079 digestive effect Effects 0.000 claims description 2
- 208000018925 gastrointestinal mucositis Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000003265 stomatitis Diseases 0.000 claims description 2
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 claims 1
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 claims 1
- 238000004220 aggregation Methods 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 238000004132 cross linking Methods 0.000 claims 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 1
- 208000003425 inflammatory bowel disease 9 Diseases 0.000 claims 1
- 229960002404 palifermin Drugs 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 30
- 230000011664 signaling Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 2
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95863407P | 2007-07-06 | 2007-07-06 | |
| US60/958,634 | 2007-07-06 | ||
| US96134307P | 2007-07-20 | 2007-07-20 | |
| US60/961,343 | 2007-07-20 | ||
| US12/215,700 | 2008-06-27 | ||
| US12/215,700 US9884899B2 (en) | 2007-07-06 | 2008-06-27 | Methods for treating fibrosis using CRP antagonists |
| PCT/US2008/008340 WO2009009034A2 (en) | 2007-07-06 | 2008-07-07 | Methods and compositions useful in the treatment of mucositis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010532787A JP2010532787A (ja) | 2010-10-14 |
| JP2010532787A5 true JP2010532787A5 (enExample) | 2012-08-16 |
| JP5329538B2 JP5329538B2 (ja) | 2013-10-30 |
Family
ID=40076757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010516038A Active JP5329538B2 (ja) | 2007-07-06 | 2008-07-07 | 粘膜炎の治療において有用な方法および組成物 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP2185581B1 (enExample) |
| JP (1) | JP5329538B2 (enExample) |
| CA (1) | CA2692682C (enExample) |
| DK (1) | DK2185581T3 (enExample) |
| ES (1) | ES2554167T3 (enExample) |
| HU (1) | HUE026850T2 (enExample) |
| PL (1) | PL2185581T3 (enExample) |
| PT (1) | PT2185581E (enExample) |
| WO (1) | WO2009009034A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8247370B2 (en) | 2006-12-04 | 2012-08-21 | Promedior, Inc. | Conjoint therapy for treating fibrotic diseases |
| US9884899B2 (en) | 2007-07-06 | 2018-02-06 | Promedior, Inc. | Methods for treating fibrosis using CRP antagonists |
| US8497243B2 (en) | 2007-07-06 | 2013-07-30 | Promedior, Inc. | Methods and compositions useful in the treatment of mucositis |
| PT2405928T (pt) | 2009-03-11 | 2017-02-07 | Promedior Inc | Métodos de tratamento e de diagnóstico para patologias de hipersensibilidade |
| CA2755047C (en) | 2009-03-11 | 2018-12-04 | Promedior, Inc. | Treatment methods for autoimmune disorders |
| UA110323C2 (en) | 2009-06-04 | 2015-12-25 | Promedior Inc | Derivative of serum amyloid p and their receipt and application |
| AU2010262847B2 (en) * | 2009-06-17 | 2016-06-02 | Promedior, Inc. | SAP variants and their use |
| CA2926418A1 (en) * | 2013-10-08 | 2015-04-16 | Promedior, Inc. | Methods for treating fibrotic cancers |
| EP3669885A1 (en) * | 2018-12-20 | 2020-06-24 | Humanitas Mirasole S.p.A. | Use of sap for the treatment of eurotiomycetes fungi infections |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992021364A1 (en) * | 1991-05-31 | 1992-12-10 | New England Deaconess Hospital Corporation | Cea-binding proteins and methods for their isolation and use |
| GB9317120D0 (en) * | 1993-08-17 | 1993-09-29 | Royal Postgrad Med School | Human serum amyloid p component |
| AU8351698A (en) * | 1997-07-23 | 1999-02-16 | Cleansorb Limited | Methods for deposition of materials in underground reservoirs |
| JP2008540510A (ja) * | 2005-05-13 | 2008-11-20 | エーザイ株式会社 | 口腔粘膜炎及び胃腸粘膜炎の症状を緩和させる方法 |
| US20070099251A1 (en) * | 2005-10-17 | 2007-05-03 | Institute For Systems Biology | Tissue-and serum-derived glycoproteins and methods of their use |
| US8247370B2 (en) * | 2006-12-04 | 2012-08-21 | Promedior, Inc. | Conjoint therapy for treating fibrotic diseases |
-
2008
- 2008-07-07 EP EP08826168.0A patent/EP2185581B1/en active Active
- 2008-07-07 ES ES08826168.0T patent/ES2554167T3/es active Active
- 2008-07-07 DK DK08826168.0T patent/DK2185581T3/en active
- 2008-07-07 HU HUE08826168A patent/HUE026850T2/en unknown
- 2008-07-07 PT PT88261680T patent/PT2185581E/pt unknown
- 2008-07-07 WO PCT/US2008/008340 patent/WO2009009034A2/en not_active Ceased
- 2008-07-07 CA CA2692682A patent/CA2692682C/en active Active
- 2008-07-07 JP JP2010516038A patent/JP5329538B2/ja active Active
- 2008-07-07 PL PL08826168T patent/PL2185581T3/pl unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010532787A5 (enExample) | ||
| Andrews et al. | Cytokine tuning of intestinal epithelial function | |
| JP5249282B2 (ja) | 新生物を治療するためのＥｒｂＢ３に基づく方法および組成物 | |
| JP2024075713A5 (enExample) | ||
| US20100093636A1 (en) | Methods of treating inflammation | |
| US20110256130A1 (en) | Methods of treating inflammatory disorders | |
| JP2019196370A5 (enExample) | ||
| JP2013533858A5 (enExample) | ||
| TWI641385B (zh) | 抗腫瘤劑及抗腫瘤效果增強劑 | |
| JPWO2019107530A5 (enExample) | ||
| JP5329538B2 (ja) | 粘膜炎の治療において有用な方法および組成物 | |
| JP2019528306A5 (enExample) | ||
| JP2018529661A5 (enExample) | ||
| US20240342211A1 (en) | Short-term activated dc1s and methods for their production and use | |
| CN113599527B (zh) | Apoe抑制剂与pd-1单抗联用在制备治疗消化道肿瘤的药物中的应用 | |
| JP2013504603A5 (enExample) | ||
| EP2970399A1 (en) | Protein particles comprising disulfide crosslinkers and uses related thereto | |
| Matsumoto-Miyai et al. | Serotonergic regulation of distention-induced ATP release from the urothelium | |
| JPWO2020229626A5 (enExample) | ||
| WO2011116245A2 (en) | Methods of treating inflammation | |
| WO2016062282A1 (zh) | 巨噬细胞发炎蛋白-1β(MIP-1β)抑制剂用以保护胰脏及防止血糖升高的用途 | |
| CN113413465B (zh) | 岩藻糖基化抑制剂在抗癌导致炎症中的应用 | |
| CN105435216B (zh) | 重组人钙调磷酸酶b亚基的应用 | |
| VB et al. | The Effectiveness of Treatment of Giant Gastric and Duodenal Ulcers with Endonasal Electrophoresis Dalargin (Tyrosyl-D-Alanyl-Glycyl-Phenylalanyl-Leucyl-Arginine Diacetate). | |
| JP2018030807A (ja) | ペプチド |